Product Pipeline: Progress, Maturity and Launches



As of July 21, 2010

Although our colorectal cancer blood test is our main focus, we are far from being a one-product company. Having consolidated our pipeline in 2007 and 2008, we now realigned and balanced our R&D portfolio with respect to time to market, market size and commercialization strategy with projects in colorectal, lung, and prostate cancer.

While we focus all our projects on diagnostic questions of highest unmet medical need, the current mix includes short-, mid- and long-term product opportunities addressing mass markets as well as high-value niches, some of which lend themselves to partnering while others, like Epi proColon are commercialized effectively by Epigenomics.

For details of our product development programms, please follow the links below:

Colon Cancer Program

Lung Cancer Program

Prostate Cancer Program